In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $14.00. The company’s shares closed last Thursday at $3.60, close to its 52-week low of $3.03.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 23.4% and a 50.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Axcella Health with a $11.80 average price target, a 224.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.
The company has a one-year high of $6.84 and a one-year low of $3.03. Currently, Axcella Health has an average volume of 322.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.